Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer

Liu, Ying; Ao, Xiang; Yu, Wanpeng; Zhang, Yuan; Wang, Jianxun

doi:10.1016/j.omtn.2021.11.013

Cited by 58 publications

(39 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer (LC) is the leading cause of cancer-related death worldwide, with a high incidence rate and mortality rate. Among them, non-small cell lung cancer (NSCLS) is the main case type of lung cancer, accounting for more than 80% of all cases [161]. Exosomes have become a new biomarker for the early treatment and detection of lung cancer.…”

Section: Applications For Cancer Detectionmentioning

confidence: 99%

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Yang

Zhang

et al. 2022

Sensors

126

View full text Add to dashboard Cite

The early diagnosis of infectious diseases is critical because it can greatly increase recovery rates and prevent the spread of diseases such as COVID-19; however, in many areas with insufficient medical facilities, the timely detection of diseases is challenging. Conventional medical testing methods require specialized laboratory equipment and well-trained operators, limiting the applicability of these tests. Microfluidic point-of-care (POC) equipment can rapidly detect diseases at low cost. This technology could be used to detect diseases in underdeveloped areas to reduce the effects of disease and improve quality of life in these areas. This review details microfluidic POC equipment and its applications. First, the concept of microfluidic POC devices is discussed. We then describe applications of microfluidic POC devices for infectious diseases, cardiovascular diseases, tumors (cancer), and chronic diseases, and discuss the future incorporation of microfluidic POC devices into applications such as wearable devices and telemedicine. Finally, the review concludes by analyzing the present state of the microfluidic field, and suggestions are made. This review is intended to call attention to the status of disease treatment in underdeveloped areas and to encourage the researchers of microfluidics to develop standards for these devices.

show abstract

Section: Applications For Cancer Detectionmentioning

confidence: 99%

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Yang

Zhang

et al. 2022

Sensors

126

View full text Add to dashboard Cite

show abstract

“…Consistent with this, the knockdown of MALAT1 reduced the inhibition of MALAT1 on the apoptosis of the CDDP-resistant GC cells. Mechanistically, MALAT1 activated the PI3K/AKT signaling pathway by upregulating the level of phosphorylated PI3K (p-PI3K) and p-AKT, leading to the enhancement of the CDDP resistance of GC cells (40) The Wnt/b−catenin signaling pathway is a conserved cancerrelated pathway participating in cancer progression by promoting CSC renewal, proliferation, and differentiation, thereby playing crucial roles in carcinogenesis and therapy response (114,115). The aberrant activation of the Wnt/ b−catenin pathway contributes to the development of drug resistance in a variety of cancers, including GC (116,117).…”

Section: Long Non-coding Rnas Target Signaling Pathways In Gastric Cancer Drug Resistancementioning

confidence: 99%

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Liu

Yü

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, with high recurrence and mortality rate. Chemotherapy, including 5-fluorouracil (5-FU), adriamycin (ADR), vincristine (VCR), paclitaxel (PTX), and platinum drugs, remains one of the fundamental methods of GC treatment and has efficiently improved patients’ prognosis. However, most patients eventually develop resistance to chemotherapeutic agents, leading to the failure of clinical treatment and patients’ death. Recent studies suggest that long non-coding RNAs (lncRNAs) are involved in the drug resistance of GC by modulating the expression of drug resistance-related genes via sponging microRNAs (miRNAs). Moreover, lncRNAs also play crucial roles in GC drug resistance via a variety of mechanisms, such as the regulation of the oncogenic signaling pathways, inhibition of apoptosis, induction of autophagy, modulation of cancer stem cells (CSCs), and promotion of the epithelial-to-mesenchymal transition (EMT) process. Some of lncRNAs exhibit great potential as diagnostic and prognostic biomarkers, as well as therapeutic targets for GC patients. Therefore, understanding the role of lncRNAs and their mechanisms in GC drug resistance may provide us with novel insights for developing strategies for individual diagnosis and therapy. In this review, we summarize the recent findings on the mechanisms underlying GC drug resistance regulated by lncRNAs. We also discuss the potential clinical applications of lncRNAs as biomarkers and therapeutic targets in GC.

show abstract

“…circRNAs exert a variety of biological functions, which include functioning as miRNA sponges, sequestering RBPs, regulating alternative splicing/transcription and gene expression, and encoding functional proteins/peptides [ 99 ]. These characteristics suggest that circRNAs serve a key role in biological cellular events and pathological processes.…”

Section: Roles Of Main Noncoding Rnas In Cancermentioning

confidence: 99%

The Targeting of Noncoding RNAs by Quercetin in Cancer Prevention and Therapy

Wang

Chen

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The dietary flavonoid quercetin is ubiquitously distributed in fruits, vegetables, and medicinal herbs. Quercetin has been a focal point in recent years due to its versatile health-promoting benefits and high pharmacological values. It has well documented that quercetin exerts anticancer actions by inhibiting cell proliferation, inducing apoptosis, and retarding the invasion and metastasis of cancer cells. However, the exact mechanism of quercetin-mediated cancer chemoprevention is still not fully understood. With the advances in high-throughput sequencing technologies, the intricate oncogenic signaling networks have been gradually characterized. Increasing evidence on the close association between noncoding RNA (ncRNAs) and cancer etiopathogenesis emphasizes the potential of ncRNAs as promising molecular targets for cancer treatment. Available experimental studies indicate that quercetin can dominate multiple cancer-associated ncRNAs, hence repressing carcinogenesis and cancer development. Thus, modulation of ncRNAs serves as a key mechanism responsible for the anticancer effects of quercetin. In this review, we focus on the chemopreventive effects of quercetin on cancer pathogenesis by targeting cancer-relevant ncRNAs, supporting the viewpoint that quercetin holds promise as a drug candidate for cancer chemoprevention and chemotherapy. An in-depth comprehension of the interplay between quercetin and ncRNAs in the inhibition of cancer development and progression will raise the possibility of developing this bioactive compound as an anticancer agent that could be highly efficacious and safe in clinical practice.

show abstract

Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer

Cited by 58 publications

References 187 publications

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

The Targeting of Noncoding RNAs by Quercetin in Cancer Prevention and Therapy

Contact Info

Product

Resources

About